The market is mispricing AbbVie by fixating on the trailing P/E and the Humira patent cliff's impact, failing to fully account for the robust growth from new immunology and oncology assets. This creates a disconnect where the forward earnings power and substantial capital return are undervalued.
Bear
$145
-31%
20%
Base
$255
+22%
60%
Bull
$295
+41%
20%
Catalysts
Stronger-than-expected sales reports for Skyrizi and Rinvoq, demonstrating rapid market share capture.
Positive clinical trial results or accelerated regulatory approval for a key pipeline asset, such as epcoritamab in new indications.
Analyst upgrades and positive re-ratings as the market gains confidence in AbbVie's post-Humira growth trajectory.
Risk Factors
Underperformance of key growth assets (Skyrizi, Rinvoq) due to increased competition or slower market adoption.
Significant pipeline failures or delays in late-stage clinical trials, impacting future growth prospects.
Unexpected pricing pressures or reimbursement challenges for new and existing drugs, eroding profitability.
Key Debates
Net Margin expands to 12%+ by Q4 on immunology ramp
Fwd P/E re-rates to 18x by H2 on pipeline execution
Gross Margin holds above 70% despite LOE by Q4
Recent Daily Analysis
— Today’s sector-lagging decline demonstrates the market's addiction to an obsolete narrative: the Humira patent cliff. Our hypothesis is that algorithmic trading, still keying off negative Humira prescription data, is driving the price action while ignoring the superior economics of its successors. The critical mechanism the market is missing is not a simple dollar-for-dollar revenue replacement, but a significant margin uplift from Skyrizi and Rinvoq. This focus on lagging top-line data has artificially suppressed the stock's multiple. Once Q1 earnings confirm the new immunology portfolio's combined operating margin is tracking above 45%, the market will be forced to re-evaluate its core assumptions, making the current 14.8x P/E look indefensible.